RIP3 Activators
The activation of RIP3, a crucial protein in the necroptotic pathway, can be modulated by various chemicals that operate through multiple mechanisms. Inhibition or neutralization of competing pathways often serves as a trigger for RIP3 activation. For instance, Z-VAD-FMK, a pan-caspase inhibitor, halts caspase activity, allowing RIP3 activation to proceed. Similarly, SM-164 and LCL161 are Smac mimetics that neutralize Inhibitor of Apoptosis Proteins (IAPs), clearing the way for RIP3-mediated necroptosis. Chemicals like 5Z-7-Oxozeaenol inhibit survival pathways like TAK1, effectively favoring RIP3 activation. It's also noteworthy that some compounds may have context-dependent effects. Necrostatin-1, primarily known as a RIP3 inhibitor, can paradoxically activate RIP3 under certain conditions.
Another mechanism involves the direct initiation of pathways that lead to RIP3 activation. For example, TNF-α activates RIP3 through the TNF receptor, while poly(I:C) and Imiquimod activate RIP3 via Toll-Like Receptor (TLR) signaling. The influence of ion balance and cellular energetics shouldn't be overlooked; compounds like Nigericin and Oligomycin disrupt ion homeostasis and energy production, respectively, leading to RIP3 activation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
Pan-caspase inhibitor that elevates RIP3 activation by inhibiting caspases that would otherwise counteract necroptosis. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
RIP3 is often rendered inactive in cancer cells due to excessive methylation of its promoter region, demethylating agents like decitabine (5-aza-2′-deoxycytidine) can be employed to revive RIP3 expression and amplify the occurrence of chemotherapy-triggered necroptosis. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Protein synthesis inhibitor that can induce RIP3-mediated necroptosis in certain cellular contexts. | ||||||
LCL-161 | 1005342-46-0 | sc-507541 | 10 mg | $360.00 | ||
Smac mimetic that, like SM-164, neutralizes IAPs and subsequently activates RIP3. | ||||||
(5Z)-7-Oxozeaenol | 253863-19-3 | sc-202055 sc-202055A | 1 mg 5 mg | $157.00 $646.00 | 13 | |
TAK1 inhibitor that can activate RIP3 by suppressing survival pathways. | ||||||
Necrostatin-1 | 4311-88-0 | sc-200142 sc-200142A | 20 mg 100 mg | $94.00 $343.00 | 97 | |
Although initially an inhibitor, it can activate RIP3 in specific conditions through off-target effects. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Inhibits vacuolar ATPases, thereby leading to the activation of RIP3 via intracellular acidification. | ||||||
Nigericin sodium salt | 28643-80-3 | sc-201518A sc-201518 sc-201518B sc-201518C sc-201518D | 1 mg 5 mg 25 mg 1 g 5 g | $46.00 $112.00 $240.00 $7079.00 $27417.00 | 9 | |
K+/H+ ionophore that causes a shift in cellular ionic balance, inducing RIP3 activation. | ||||||
Oligomycin | 1404-19-9 | sc-203342 sc-203342C | 10 mg 1 g | $149.00 $12495.00 | 18 | |
Inhibits mitochondrial ATP synthase, creating an energy crisis that can activate RIP3. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
TLR7 agonist that activates RIP3 through TLR7 signaling. | ||||||